Overexpression and Accumulation of Apolipoprotein E as a Cause of Hypertriglyceridemia
Open accessAbstract
The molecular mechanisms of hypertriglyceridemia (HTG), a common lipid metabolic disorder in humans, often of genetic origin, are not well understood. In studying the effect of apolipoprotein (apo) E on the metabolism of triglyceride-rich lipoproteins, we found that expressing high plasma levels of human apoE3 in transgenic mice lacking endogenous mouse apoE caused HTG. These transgenic animals had 3-fold higher plasma triglyceride levels, higher very low density lipoproteins (VLDL), and lower high density lipoproteins than did nontransgenics. Removing one or both low density lipoprotein receptor alleles in the apoE3-overexpressing mice caused severe HTG (8-11-fold over nontransgenics) and increased VLDL and decreased low and high density lipoproteins, and apoE3-enriched VLDL were markedly depleted in apoC-II. At least two mechanisms could explain HTG associated with apoE3 overexpression: stimulated VLDL triglyceride production and impaired VLDL lipolysis. The apoE3 mice with HTG had a 50% increase in hepatic VLDL triglyceride production. Furthermore, overexpression of apoE (E2, E3, or E4) in cultured hepatocytes (McA-RH7777 cells) correlated positively with secretion of VLDL into the medium. However, apoE3 overexpression-associated HTG was only partially explained by VLDL overproduction, as lipoprotein lipase-mediated VLDL lipolysis was also decreased 20-86% depending on apoE3 levels, most likely by displacing or masking apoC-II on the particles. In human subjects, HTG correlated positively with increased VLDL triglyceride and plasma and VLDL apoE levels. However, plasma and VLDL apoE correlated negatively with VLDL apoC-II levels and lipoprotein lipase-mediated VLDL lipolysis. Thus, optimal expression of apoE is crucial for normal metabolism of triglyceride-rich lipoproteins, and overexpression and/or accumulation of apoE may contribute to HTG by stimulating VLDL triglyceride production and by impairing VLDL lipolysis. The apoE3-overexpressing mice will be useful for studying the pathophysiology of this disorder.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ApoE4, which is abundant on VLDL and chylomicrons, tends to inhibit triglyceride degradation by LPL more readily than apoE2 or apoE3.
“Therefore, apoE4, which is abundant on VLDL and chylomicrons, tends to inhibit triglyceride degradation by LPL more readily than apoE2 or apoE3 21).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [21]
The Results report that apoE3-enriched VLDL inhibits LPL-mediated lipolysis and note a similar effect for apoE2-enriched VLDL. They do not establish that apoE4 inhibits lipolysis more readily than either isoform, or that apoE4 is abundant on both VLDL and chylomicrons. The Results’ comparison of all three isoforms concerns VLDL production, not LPL-mediated lipolysis. (LLM, conf=0.86)
Experimental — accuracy not yet measuredOverexpression or accumulation of APOE stimulates the production of VLDL triglycerides, leading to hypertriglyceridemia.
“However, overexpression or accumulation of APOE stimulates the production of VLDL triglycerides [33], leading to hypertriglyceridemia.”
Hypertriglyceridemic patients have higher plasma levels of apoE compared with normal control subjects.
“Hypertriglyceridemic patients have higher plasma levels of apoE compared with normal control subjects; this could probably be explained by the finding, that increased levels of apoE stimulate VLDL triglyceride production in the liver and impairs lipoprotein lipase-mediated lipolysis, thus leading to hypertriglyceridemia [56,65].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [65]
Increased levels of apoE stimulate very low-density lipoprotein triglyceride production in the liver and impair lipoprotein lipase-mediated lipolysis, leading to hypertriglyceridaemia.
“increased levels of apoE stimulate very low-density lipoprotein triglyceride production in the liver and impairs lipoprotein lipase-mediated lipolysis, thus leading to hypertriglyceridaemia.42,43”
In vitro, increased apoE expression by hepatoma cells correlates with increased very low-density lipoprotein synthesis and/or secretion irrespective of apoE isoform.
“in vitro increase in apoE expression by hepatoma cells correlates with increased very low-density lipoprotein synthesis and/or secretion irrespective of apoE isoform.42”
Hypertriglyceridaemic patients have higher plasma levels of apoE compared with normal control subjects.
“Hypertriglyceridaemic patients have higher plasma levels of apoE compared with normal control subjects”
In mice, overexpression of apoE leads to hypertriglyceridaemia.
“In mice, overexpression of apoE has been shown to lead to hypertriglyceridaemia”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 46 · Cited by 204
Research works printed but not linked: 1
- Ehnholm, C., Mahley, R. W., Chappell, D. A., Weisgraber, K. H., Ludwig, E., and Witztum, J. L. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 5566 -5570
- Authors
- Huang, Y., Liu, X. Q., Rall, S. C., Taylor, J. M., von Eckardstein, A., Assmann, G., & Mahley, R. W.
- Affiliations
- Gladstone Institutes (US)
- University of Münster (DE)
- Corresponding author
- Mahley, Robert W.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1998-10
- Volume
- 273
- Issue
- 41
- Pages
- 26388-26393
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2049314229
- Cited by
- 204
- References
- 46
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 7 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 7 · 2014: 9 · 2013: 3 · 2012: 9
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01hl047660-10)
- National Heart, Lung, and Blood Institute (HL-47660)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- apolipoprotein E, hypertriglyceridemia, lipoprotein lipase, LDL receptor, triglyceride-rich lipoproteins, hepatic VLDL secretion, transgenic mice, APOE isoforms
- MeSH terms
- Animals, Apolipoproteins E, Humans, Lipolysis, Lipoproteins, VLDL, Mice, Transgenic, Receptors, LDL, Triglycerides, Tumor Cells, Cultured, Hypertriglyceridemia, Mice, Knockout, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review